Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332017 | Endometrium | EEC | regulation of protein modification by small protein conjugation or removal | 72/2168 | 242/18723 | 1.45e-14 | 4.36e-12 | 72 |
GO:000645715 | Endometrium | EEC | protein folding | 63/2168 | 212/18723 | 6.82e-13 | 1.40e-10 | 63 |
GO:001049817 | Endometrium | EEC | proteasomal protein catabolic process | 112/2168 | 490/18723 | 6.99e-13 | 1.40e-10 | 112 |
GO:003139617 | Endometrium | EEC | regulation of protein ubiquitination | 62/2168 | 210/18723 | 1.42e-12 | 2.76e-10 | 62 |
GO:007259415 | Endometrium | EEC | establishment of protein localization to organelle | 94/2168 | 422/18723 | 2.22e-10 | 2.51e-08 | 94 |
GO:004316117 | Endometrium | EEC | proteasome-mediated ubiquitin-dependent protein catabolic process | 92/2168 | 412/18723 | 3.01e-10 | 3.23e-08 | 92 |
GO:003497617 | Endometrium | EEC | response to endoplasmic reticulum stress | 63/2168 | 256/18723 | 3.84e-09 | 2.71e-07 | 63 |
GO:006145815 | Endometrium | EEC | reproductive system development | 91/2168 | 427/18723 | 4.54e-09 | 3.13e-07 | 91 |
GO:004860814 | Endometrium | EEC | reproductive structure development | 90/2168 | 424/18723 | 6.77e-09 | 4.41e-07 | 90 |
GO:004851114 | Endometrium | EEC | rhythmic process | 67/2168 | 298/18723 | 5.86e-08 | 3.11e-06 | 67 |
GO:000660517 | Endometrium | EEC | protein targeting | 69/2168 | 314/18723 | 9.61e-08 | 4.69e-06 | 69 |
GO:003596617 | Endometrium | EEC | response to topologically incorrect protein | 41/2168 | 159/18723 | 5.20e-07 | 2.00e-05 | 41 |
GO:000698617 | Endometrium | EEC | response to unfolded protein | 37/2168 | 137/18723 | 5.40e-07 | 2.04e-05 | 37 |
GO:006107715 | Endometrium | EEC | chaperone-mediated protein folding | 23/2168 | 67/18723 | 8.50e-07 | 2.98e-05 | 23 |
GO:004325417 | Endometrium | EEC | regulation of protein-containing complex assembly | 83/2168 | 428/18723 | 1.44e-06 | 4.64e-05 | 83 |
GO:004518517 | Endometrium | EEC | maintenance of protein location | 28/2168 | 94/18723 | 1.55e-06 | 4.86e-05 | 28 |
GO:007097215 | Endometrium | EEC | protein localization to endoplasmic reticulum | 24/2168 | 74/18723 | 1.59e-06 | 4.96e-05 | 24 |
GO:003250716 | Endometrium | EEC | maintenance of protein location in cell | 21/2168 | 65/18723 | 7.55e-06 | 1.73e-04 | 21 |
GO:007155914 | Endometrium | EEC | response to transforming growth factor beta | 54/2168 | 256/18723 | 8.25e-06 | 1.83e-04 | 54 |
GO:002176216 | Endometrium | EEC | substantia nigra development | 16/2168 | 44/18723 | 1.71e-05 | 3.26e-04 | 16 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa030609 | Breast | Precancer | Protein export | 6/684 | 23/8465 | 8.34e-03 | 4.54e-02 | 3.48e-02 | 6 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0306012 | Breast | Precancer | Protein export | 6/684 | 23/8465 | 8.34e-03 | 4.54e-02 | 3.48e-02 | 6 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0502023 | Breast | IDC | Prion disease | 102/867 | 273/8465 | 3.70e-34 | 4.01e-32 | 3.00e-32 | 102 |
hsa0501423 | Breast | IDC | Amyotrophic lateral sclerosis | 102/867 | 364/8465 | 1.29e-22 | 5.22e-21 | 3.91e-21 | 102 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HSPA5 | SNV | Missense_Mutation | | c.887N>C | p.Lys296Thr | p.K296T | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | | c.211N>A | p.Glu71Lys | p.E71K | P11021 | protein_coding | deleterious_low_confidence(0.03) | benign(0.02) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
HSPA5 | SNV | Missense_Mutation | novel | c.414N>T | p.Lys138Asn | p.K138N | P11021 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.902) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | rs368840257 | c.1595G>A | p.Arg532His | p.R532H | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.956) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HSPA5 | SNV | Missense_Mutation | | c.1540N>C | p.Glu514Gln | p.E514Q | P11021 | protein_coding | tolerated_low_confidence(0.24) | probably_damaging(0.982) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
HSPA5 | SNV | Missense_Mutation | rs191087735 | c.395N>C | p.Ile132Thr | p.I132T | P11021 | protein_coding | tolerated_low_confidence(0.13) | benign(0.012) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HSPA5 | SNV | Missense_Mutation | novel | c.433N>G | p.Ile145Val | p.I145V | P11021 | protein_coding | tolerated_low_confidence(0.38) | benign(0.011) | TCGA-S3-AA12-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
HSPA5 | SNV | Missense_Mutation | rs762582529 | c.971N>A | p.Arg324Gln | p.R324Q | P11021 | protein_coding | deleterious_low_confidence(0.03) | benign(0.368) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HSPA5 | SNV | Missense_Mutation | | c.1712N>A | p.Ser571Tyr | p.S571Y | P11021 | protein_coding | tolerated_low_confidence(0.05) | benign(0.114) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
HSPA5 | SNV | Missense_Mutation | novel | c.949N>T | p.Asp317Tyr | p.D317Y | P11021 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | STROBOPININ | STROBOPININ | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | TCMDC-123749 | CHEMBL524376 | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | NORGESTREL | NORGESTREL | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | MIANSERIN | MIANSERIN | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | AG-490 | CHEMBL56543 | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | CHLORQUINALDOL | CHLORQUINALDOL | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | SAM-6 | | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB] | 5-NITRO-2-PHENYLPROPYLAMINOBENZOIC ACID [NPPB] | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | THAPSIGARGIN | THAPSIGARGIN | |
3309 | HSPA5 | TRANSPORTER, ENZYME, PROTEASE INHIBITOR, CELL SURFACE, DRUGGABLE GENOME | | NKP-1339 | IT-139 | |